Addition of the p110[alpha] inhibitor BYL719 overcomes targeted therapy resistance in cells from Her2-positive-PTEN-loss breast cancer

Breast cancer is one of the leading causes of death for women worldwide. Among various subtypes of breast cancer, human epidermal growth factor receptor 2 (HER2)-positive and phosphatase and tensin homolog (PTEN) loss breast cancer is a cause of great concern in terms of its resistance to HER2-targe...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Tumor biology 2016-11, Vol.37 (11), p.14831
Hauptverfasser:	Zhang, Chen, Xu, Bingfei, Liu, Pian
Format:	Artikel
Sprache:	eng
Schlagworte:	Breast cancer Cells Drug resistance Drug therapy
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!